Luke Greenwalt, MBA, on the Current Market Conditions for New Drug Launches | Asembia's AXS25 Summit
The vice president and lead of IQVIA's Market Access Center of Excellence says fewer drugs are hitting the $100 million mark during their first year on the market than in the past.
In this segment of an interview with Managed Healthcare Executive (MHE) conducted before his talk at 2025 Asembia's AXS25 Summit in Las Vegas, Luke Greenwalt discusses new drug launches. Greenwalt, vice president and lead of the Market Access Center of Excellence at IQVIA and a member of the MHE editorial advisory board, noted that in the past five years, fewer drugs are achieving $100 million of sales in their first year than in the previous five years. On the other hand, more newly launched drugs have hit the $1 billion mark in their inaugural year recently. "We're seeing very, very successful products come into the market, such as RSV [respiratory syncytial virus] vaccines and the GLP-1s [glucagon-like peptide 1s] for obesity and diabetes treatment." Greenwalt noted, though, that there is greater payer control than ever before.
GLP-1 Tiering Agreement Reached, Says Optum Rx President
May 3rd 2024Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,
Read More
Specialty Pharmacies Drive Cost Savings in Value-Based Care | Asembia 2024
May 2nd 2024Earlier this week at the 2024 Asembia Specialty Pharmacy Summit in Las Vegas, Managed Healthcare Executive editors spoke with Bill McElnea, vice president of population health at Shields Health Solutions, about specialty pharmacies reducing costs for patients.
Read More
